Eupraxia Pharmaceuticals Inc.

RunWithRugs · 2026-03-20T17:10:18+00:00

Eupraxia Pharmaceuticals Inc. reported positive symptom data from its RESOLVE trial's highest dose cohorts for EP-104GI, targeting eosinophilic esophagitis, with shares currently stable at $10.13.

RunWithRugs

2026-03-20 17:10:18

Abstract generation in progress

(MENAFN- Baystreet) 08:43 AM EST - Eupraxia Pharmaceuticals Inc.: Announced positive symptom data from patients in the two highest dose cohorts from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis. Eupraxia Pharmaceuticals Inc. shares T are trading ** unchanged** at $10.13.

MENAFN17032026000212011056ID1110872538

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes